The global population is ageing faster than ever before. In 2019, life expectancy at birth reached 72.8 years almost 9 years more than in 1990. In this context, staying healthy and active as we grow older is becoming increasingly important, especially considering that more than 50% of the global disease burden in adults is linked to age-related conditions.
As we age, our bodies tend to develop a state of low-grade, chronic inflammation known as “inflammaging”, and the composition of the gut microbiota changes significantly. Diet, lifestyle and age-related physiological changes promote a condition of gut dysbiosis which, together with inflammaging, can contribute to frailty, loss of function and a higher risk of disease.
In this scenario, Sacco System presents SYNBIO®, a clinically studied probiotic blend designed to help counteract processes linked to inflammaging and support healthy ageing. SYNBIO® is part of the CultureScience portfolio, a selection of clinically validated probiotic strains strategically formulated to address key health needs across different life stages. These solutions are available both as single strains and as pre-formulated blends, all evaluated in gold-standard clinical trials that confirm their efficacy.
Probiotic supplementation is gaining attention for its role in maintaining health and enhancing the quality of life of the elderly. Leukocyte Telomere Length (LTL) is a biomarker of cellular ageing, with shorter LTL associated with cardiovascular morbidity and mortality. This study explored whether probiotics could counteract LTL attrition in an ethnically homogeneous cohort of older adults over a six-month period.
Samples were selected from the PROBIOSENIOR trial, a randomized, double blind, placebo-controlled study involving 46 participants (≥60 years). Participants were randomized to receive either SYNBIO® probiotics (5×10⁹ CFU/daily dose) or placebo for six months. Genomic DNA was extracted from blood samples at baseline, and six months later; LTL measures were obtained via quantitative PCR. A general linear model assessed the “treatment x time” interaction as the main outcome.
LTL was successfully assessed for all participants (N= 46×2 time points). Statistical analysis revealed a significant “treatment x time” interaction (P=0.034), indicating a reduced LTL attrition rate in the probiotic group compared to the placebo group.
A six-month supplementation with SYNBIO® probiotics significantly reduced LTL attrition in an ethnically homogeneous cohort of elderly adults. These findings suggest that probiotics may serve as a simple and effective intervention to mitigate cellular senescence and promote healthy ageing.
The growing global burden of age-related conditions highlights the need for safe, accessible strategies that support healthy ageing. Ageing is accompanied by profound changes in gut microbiota composition and a chronic inflammatory state known as inflammaging, both of which contribute to physiological decline and increased disease risk. In this context, the SYNBIO® probiotic blend offers a promising approach to help counteract these processes. Findings from the PROBIOSENIOR clinical study demonstrate that six months of SYNBIO® supplementation can significantly reduce leukocyte telomere length attrition, suggesting a beneficial effect on cellular ageing. Together with its documented anti-inflammatory potential, SYNBIO® represents a compelling candidate for innovative formulations designed to maintain physiological resilience, promote longevity, and enhance quality of life in older adults.
SYNBIO® is a natural ingredient that supports healthy ageing; improves inflammaging through modulation of the gut microbiota and the SCFA pool. Supplementation with SYNBIO® may modulate key biomarkers of sarcopenia in elderly subjects and improve the nutritional status of the elderly, reducing the risk of malnutrition.
In a constantly evolving global market, innovation represents the key driver of competitiveness and sustainability. Sacco System is a pioneer of innovation in the field of lactic acid bacteria and food biotechnology. Drawing on deep scientific expertise, Sacco System integrates technological innovation (from applied genomics and microbial strain engineering to advanced production processes) with product innovation, offering customized solutions that meet consumer needs for taste, health, and well-being.
The company succeeds in translating cutting-edge research into successful final products, helping to redefine quality standards and promote a more efficient, safe, and sustainable food industry. All of this is made possible through a strong focus on technological and process innovation, sustainability, and the development of human capital.
Read the full study here: https://pubmed.ncbi.nlm.nih.gov/41335484/